Biography
Adam Perriman is a Professor of Bioengineering at the School of Cellular and Molecular Medicine, University of Bristol, and Director of the Bristol Centre for Bioprinting. He is also the founder of the cell therapy technology company CytoSeek.
Internationally distinguished for his pioneering research on the construction and study of novel synthetic biomolecular systems, and his research interests span the fields of synthetic biology, biophysics and tissue engineering. His research is frequently featured in top-tier journals, including Nature Chemistry, Nature Communications, the Journal of the American Chemical Society, Small, and Advanced Materials.
His research into the development of novel biomaterials has also generated extensive media coverage and has been featured nationally in RSC’s Chemistry World, The Chemical Engineer, New Scientist, and internationally in Nature, Nature Chemistry and Chemical and Engineering News (C&EN). This research also led to nationally-broadcast interviews on BBC4.
His significant advances in these areas have resulted in invited presentations at major international conferences, including the Materials Research Society (MRS) meetings and Gordon conferences. His contributions to the field of interdisciplinary science led to him being named a Wellcome Trust Frontiers Innovator in 2015, and in 2016, he was awarded the prestigious British Biophysical Society Young Investigator's Award and Medal. In 2019, he was named a UK Research and Innovation Future Leaders Fellow.